Modulating the Gut Microbiota via Rectal Ozone Insufflation in Gynecological Cancer Patients with Radiotherapy/Chemotherapy-Induced Pelvic Toxicity: A Proposed Clinical Study Protocol
Year: 2025
Type: article
Study design: Study Protocol
Abstract: BACKGROUND: Chronic pelvic toxicity induced by radiotherapy and/or chemotherapy (R/CIPT) is a debilitating sequela in gynecological cancer survivors, often refractory to conventional treatments and potentially linked to gut microbiota dysbiosis. Ozone therapy (OT), particularly rectal insufflation, demonstrates anti-inflammatory and redox-modulating effects through hormetic mechanisms (Nrf2 activation/NF-κB inhibition). We hypothesize that its clinical benefit is mediated, in part, by restoring gut microbial homeostasis. OBJECTIVE: This manuscript proposes a clinical study to evaluate the impact of rectal OT on the gut microbiota of patients with gynecological cancers and chronic R/CIPT. Proposed Methods: A prospective, observational study of 38 patients is outlined: 19 with CTCAE v5.0 Grade ≥2 chronic R/CIPT receiving compassionate rectal OT (~40 sessions over 4 months), and 19 matched controls without toxicity. Stool samples for 16S rRNA sequencing will be collected from the OT group pre- and post-intervention and once from controls. Primary endpoints are changes in microbiota composition/diversity and pelvic toxicity scores (CTCAE v5.0, EORTC QLQ-CX24). Secondary endpoints include quality of life (EORTC QLQ-C30, EQ-5D-5L), anxiety/depression (HADS), and serum inflammatory/oxidative stress biomarker analysis. Anticipated Results and Conclusion: This will be the first study to prospectively investigate whether rectal OT's effect correlates with a beneficial shift in the gut microbiota, specifically an increase in commensals (e.g., short-chain fatty acids producers) and a decrease in pathobionts. If successful, OT could be assessed as a novel, microbiota-targeting intervention for R/CIPT. The findings from this pilot study will provide the necessary groundwork for a future randomized controlled trial to definitively establish causality and efficacy.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm14228015
Authors: Bernardino Clavo, Elizabeth Córdoba-Lanús, Gregorio Martínez-Sánchez, Mario Federico, Ángeles Cánovas-Molina, José E. Piñero, Ana M. Vargas-Prado, Avinash Ramchandani, Marta Zajac, Ivone Ribeiro, Minerva Navarro, Ignacio J. Jorge, Jesús M. González-Martín, Ruth Martín-Alfaro, María Fernández-Tagarro, Juan A. Díaz-Garrido, Jacob Lorenzo-Morales, Francisco Rodríguez-Esparragón
Institutions: Universidad de Las Palmas de Gran Canaria, Universidad de La Laguna, Instituto de Salud Carlos III, Hospital Universitario de Gran Canaria Doctor Negrín, Centro de Investigación Biomédica en Red, Fundación Canaria de Investigación Sanitaria, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Cognition, Santé, Société, Hospital Universitario Insular de Gran Canaria, Universidad Fernando Pessoa Canarias
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W4416138469
